Search hospitals > Michigan > Port Huron
McLaren-Port Huron
Claim this profilePort Huron, Michigan 48060
Global Leader in Breast Cancer
Conducts research for Esophageal Cancer
Conducts research for Breast cancer
Conducts research for Prostate Cancer
Conducts research for Lung Cancer
48 reported clinical trials
11 medical researchers
Summary
McLaren-Port Huron is a medical facility located in Port Huron, Michigan. This center is recognized for care of Breast Cancer, Esophageal Cancer, Breast cancer, Prostate Cancer, Lung Cancer and other specialties. McLaren-Port Huron is involved with conducting 48 clinical trials across 81 conditions. There are 11 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Anteneh A. Tesfaye, and Mohammed N. Al Hallak.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
2Esophageal Cancer
Stage IV
Stage III
HER2 negative
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute2 years of reported clinical research
Expert in Breast Cancer
Expert in Squamous Cell Carcinoma
29 reported clinical trials
45 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute5 years of reported clinical research
Studies Solid Tumors
Studies Pancreatic Cancer
22 reported clinical trials
65 drugs studied
Anteneh A. TesfayeWayne State University/Karmanos Cancer Institute5 years of reported clinical research
Studies Colorectal Cancer
Studies Uterine Tumors
19 reported clinical trials
39 drugs studied
Mohammed N. Al HallakWayne State University/Karmanos Cancer Institute4 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
17 reported clinical trials
33 drugs studied
Clinical Trials running at McLaren-Port Huron
Esophageal Cancer
Esophageal Adenocarcinoma
Gastric cancer
Breast Cancer
Esophageal cancer
Lung Cancer
Gastric Cancer
Stomach Cancer
Prostate Cancer
Gastroesophageal Junction Adenocarcinoma
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at McLaren-Port Huron?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.